One-Liner
A mobile coaching and adherence app for Southeast Asian domestic workers and informal laborers using newly FDA-approved oral GLP-1 medication — killed by wealth filter: drug retail price far exceeds informal worker income with no third-party payer.
AI Thinking Process
FDA approved Foundayo (oral GLP-1) on 2026-04-01. SEA opportunity for informal workers with rising obesity rates and barrier to injectable distribution.
G019 wealth filter: SEA informal worker cannot afford $400–800/month US retail price for oral GLP-1. Hard wealth-filter fail.
Attempted to find third-party payer: (a) employer of domestic worker — misaligned incentive, (b) sending-country government program — does not exist for obesity drugs, (c) local insurer (Philhealth, BPJS) — no obesity drug coverage. All three payer pivots failed.
Wealth filter fails for direct consumer; no third-party payer with aligned incentives. Drug pricing barrier dominates — even with global tiered pricing, reaching $30/month for SEA informal workers is years away. Killed.
Kill Reason
Wealth filter fails at the individual consumer level. Oral GLP-1 (Foundayo/orforglipron) retail price in the US is expected at $400–800/month — months of income for a SEA informal worker. No third-party payer has aligned incentives: employers of domestic workers will not pay for weight-loss drugs, sending-country governments have no obesity drug coverage program, and statutory health insurance in Indonesia/Philippines/Vietnam does not cover obesity drugs. Drug pricing barrier is fundamental, not positional.
Risk Analysis
Risk analysis available for latest engine ideas.
What do you think?
Related ideas you can explore free:
killed: Wealth filter fails at the individual consumer level. Oral GLP-1 (Foundayo/orforglipron) retail price in the US is expected at $400–800/month — months of income for a SEA informal worker. No third-party payer has aligned incentives: employers of domestic workers will not pay for weight-loss drugs, sending-country governments have no obesity drug coverage program, and statutory health insurance in Indonesia/Philippines/Vietnam does not cover obesity drugs. Drug pricing barrier is fundamental, not positional.
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.